Cover Image
市場調查報告書

全球前列腺癌疫苗臨床實驗平台分析

Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015

出版商 PNS Pharma 商品編碼 322940
出版日期 內容資訊 英文 155 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球前列腺癌疫苗臨床實驗平台分析 Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015
出版日期: 2015年01月15日 內容資訊: 英文 155 Pages
簡介

本報告提供全球前列腺癌疫苗市場相關調查、市場概要、上市藥簡介、各企業、國家、階段臨床實驗分析、臨床開發階段的藥物、臨床實驗停止、中止的藥物簡介及競爭情形等彙整資料,為您概述為以下內容。

第1章 前列腺癌的簡介

第2章 前列腺癌疫苗的機制

第3章 全球前列腺癌疫苗市場動態

  • 有利的市場參數
  • 行銷&商業化的課題

第4章 全球前列腺癌疫苗市場展望

  • 目前市場情況
  • 全球前列腺癌疫苗開發平台概要

第5章 全球前列腺癌疫苗市場未來發展預測

第6章 定做癌症疫苗市場機會

第7章 全球前列腺癌疫苗臨床實驗分析:各企業、國家、階段

  • 研究
  • 前臨床
  • 階段I
  • 階段I/II
  • 階段II
  • 階段III

第8章 已上市前列腺癌疫苗:各企業、各國

第9章 在臨床實驗中中止、停止了的前列腺癌疫苗

  • 未開發
  • 中止
  • 停止

第10章 競爭環境

  • Adamis Pharmaceuticals
  • Aduro BioTech
  • Bellicum Pharmaceuticals
  • CytoVac
  • Dendreon Corporation
  • Generex Biotechnology Corporation
  • Immunovaccine
  • Oncbiomune
  • Progenics
  • Sotio

圖表

目錄

Prostate cancer has emerged as a disease with one of the highest incidences and mortality rates in males across the world. This situation has created a large unmet medical demand for better therapeutics by patients suffering from prostate cancer due to modest response generated by presently available therapeutics. Hormone based therapeutics and chemotherapeutics helped in improving the patient's condition but they have side effects and modest pharmacological benefits reflecting necessity for better product. Pharmaceutical companies focused their efforts to resolve this problem by increasing research and development activities by diverging more funds in this segment. As a result, prophylactic prostate cancer vaccine was developed and introduced in market which is going to witness competition from innovative products in next few years.

Prostate cancer vaccine is a recent development which is more potent than presently available prostate cancer therapeutics in providing better medical care. Prophylactic nature of this vaccine makes it possible to prevent the future incidences of prostate cancer. Besides, it can also prevent the relapse, provides long- term immunity, decrease morbidity and mortality rates along with increasing longevity. Owing to these benefits offered by prostate cancer vaccines their acceptance is increasing among patients and physicians in recent years. It is expected that due competition and increased number of products in market will cause decrease in the price of prostate cancer vaccines in coming years.

Prostate cancer vaccine utilizes different antigens like Prostate-Specific Membrane Antigen, Prostate-Specific Antigen (PSA) and Prostatic Acid Phosphatase (PAP) in pharmacological formulations. These antigens are isolated from the prostate tumor and injected into the body to activate the immune cells. They identify these antigens as non-self and begin to search and eliminate cancerous cells from body to prevent proliferation of cancerous cells. Highly specific nature causes elimination of cancerous cells in prostate while sparing normal cells leading to minimized side effects in patients.

Prostate cancer vaccines are prophylactic in nature due to which they can prevent the future incidences of cancer. Immune cells are primed to search and eliminate the cancerous cells due to which they are able to prevent relapse. Circulating cancerous cells are also targeted responsible for secondary cancer development is checked in the body. Efficacy of cancer vaccine could be monitored by checking PSA levels which may indicate improvement in patient's condition. However, these results may vary from patient to patient but significant improvement has been observed as compared to conventional therapeutic methods. Besides pharmacological benefits, this fact also reflects towards high marketing potential of prophylactic prostate cancer vaccine.

"Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015" Report Highlights:

  • Introduction to Prostate Cancer Vaccine
  • Mechanism of Prostate Cancer Vaccine
  • Global Prostate Cancer Vaccine Clinical Trial Insight by Company, Country & Phase
  • Global Prostate Cancer Vaccine Clinical Pipeline: 41 Vaccines
  • Majority Prostate Cancer Vaccine in Phase-II: 10 Vaccines
  • Marketed Prostate Cancer Vaccine: 1 (Provenge by Dendreon Corporation)

Table of Contents

1. Introduction to Prostate Cancer Vaccine

2. Mechanism of Prostate Cancer Vaccine

3. Global Prostate Cancer Vaccine Market Dynamics

  • 3.1 Favorable Market Parameters
  • 3.2 Marketing & Commercialization Challenges

4. Global Prostate Cancer Vaccine Market Outlook

  • 4.1 Current Market Scenario
  • 4.2 Global Prostate Cancer Vaccines Pipeline Overview

5. Global Prostate Cancer Vaccine Market Future Prospects

6. Personalized Cancer Vaccine Market Opportunities

7. Global Prostate Cancer Vaccines Clinical Trial Insight by Company, Country & Phase

  • 7.1 Research
  • 7.2 Preclinical
  • 7.3 Phase-I
  • 7.4 Phase-I/II
  • 7.5 Phase-II
  • 7.6 Phase-III

8. Marketed Prostate Cancer Vaccines by Company & Country

9. Suspended & Discontinued Prostate Cancer Vaccines in Clinical Trials

  • 9.1 No Development Reported
  • 9.2 Discontinued
  • 9.3 Suspended

10. Competitive Landscape

  • 10.1 Adamis Pharmaceuticals
  • 10.2 Aduro BioTech
  • 10.3 Bellicum Pharmaceuticals
  • 10.4 CytoVac
  • 10.5 Dendreon Corporation
  • 10.6 Generex Biotechnology Corporation
  • 10.7 Immunovaccine
  • 10.8 Oncbiomune
  • 10.9 Progenics
  • 10.10 Sotio
  • Figure 1-1: Functions of Prostate Gland
  • Figure 1-2: Factors Responsible for Increasing Prostate Cancer Incidences
  • Figure 1-3: Different Methods of Prostate Cancer Treatment
  • Figure 2-1: Mechanism of Cancer Vaccines
  • Figure 2-2: Classification of Cancer Vaccines
  • Figure 2-3: Benefits of Prostate Cancer Vaccines
  • Figure 3-1: Drivers for Prostate Cancer Vaccines Market
  • Figure 3-2: Challenges for Prostate Cancer Vaccines Market
  • Figure 4-1: Prostate Cancer Vaccines Pipeline by Phase (%)
  • Figure 4-2: Prostate Cancer Vaccines Pipeline by Phase (Number of Drugs)
  • Figure 4-3: No Development Reported in Prostate Cancer Vaccines Pipeline by Phase (%)
  • Figure 4-4: No Development Reported in Prostate Cancer Vaccines Pipeline by Phase (Number of Drugs)
  • Figure 4-5: Discontinued Prostate Cancer Vaccines Pipeline by Phase (%)
  • Figure 4-6: Discontinued Prostate Cancer Vaccines Pipeline by Phase (Number of Drugs)
  • Figure 4-7: Suspended Prostate Cancer Vaccines Pipeline by Phase (%)
  • Figure 4-8: Suspended Prostate Cancer Vaccines Pipeline by Phase (Number of Drugs)
  • Figure 6-1: Personalized Cancer Vaccines Development Process
  • Figure 6-2: Personalized Cancer Vaccine Development Methodology
  • Figure 6-3: Skin Implant for Cancer Vaccine
  • Figure 10-1: Adamis Pharmaceuticals Pipeline
  • Figure 10-2: Bellicum Pharmaceuticals Pipeline
  • Figure 10-3: cytovac Pipeline
  • Figure 10-4: Generex Biotechnology Clinical Pipeline Overview
  • Figure 10-5: Immunovaccine Clinical Pipeline Overview
  • Table 6-1: Different Types of Biomarkers For Personalized Cancer Vaccine Development
Back to Top